This article is more than 5 years old. Information may no longer be current.

ThromboGenics reports steep climb in revenue

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LEUVEN, Belgium — ThromboGenics saw its revenues climb to €75 million in the first 3 months of 2012 compared to no revenue in same period last year, the company announced in a press release.

The revenue came entirely from upfront payments from Alcon after the companies reached an agreement for marketing ocriplasmin outside the U.S.

“ThromboGenics has made a positive start to 2012. Our strategic agreement with Alcon, the world leader in eye care, provides us with the ideal partner to commercialize ocriplasmin outside the U.S. We will also benefit from Alcon’s significant clinical development expertise as we jointly fund the evaluation of ocriplasmin for additional ophthalmic indications,” Patrik De Haes, MD, CEO of ThromboGenics, said in the release.

As of March 31, ThromboGenics reported €127 million in cash and cash investments, up from €101.1 million in the first quarter of 2011, the release said. Research and development expenses fell to €2.4 million from €3.7 million in the same period last year. Selling and marketing expenses rose from €1.1 million to €1.5 million.

A biologics license application for ocriplasmin as treatment for symptomatic vitreomacular adhesion has been resubmitted to the U.S. Food and Drug Administration for priority review, the release said. The company said it is preparing for the potential launch of ocriplasmin in the U.S. by early 2013.